Sermorelin: How It Differs From Growth Hormone

Sermorelin is often sold as "the natural alternative to HGH," which is half true and wholly misleading. It does not contain growth hormone. It is a signal that asks your pituitary gland to release its own, and that difference shapes everything: how it works, who it can work for, what the evidence covers and what the risks might be.

Growth hormone versus a growth hormone signal

Growth hormone (GH) is made and released by the pituitary gland at the base of the brain, mostly in pulses and largely during deep sleep. It acts throughout the body, and much of its effect runs through a second hormone, insulin-like growth factor 1 (IGF-1), produced mainly in the liver.

The pituitary does not release GH on its own initiative. The hypothalamus sends it two competing messages: growth hormone-releasing hormone (GHRH), which says "release," and somatostatin, which says "hold." IGF-1 also feeds back to dampen the system when levels rise. The result is a self-regulating loop.

That gives two very different ways to raise GH activity:

• Give growth hormone itself (somatropin). This bypasses the pituitary and the feedback loop. Somatropin products are FDA-approved for specific conditions, such as diagnosed growth hormone deficiency.
• Give a releasing signal, such as sermorelin. This works upstream, asking the pituitary to release more of its own GH, while somatostatin and IGF-1 feedback still apply.

Natural GHRH is 44 amino acids long. Researchers found that the first 29 carry its activity, and sermorelin is a synthetic copy of that 29-amino-acid stretch.

Sermorelin vs growth hormone at a glance

Was sermorelin FDA-approved?

Yes, once. The history is worth getting exactly right, because it is often garbled in both directions.

According to a 2013 FDA notice in the Federal Register, sermorelin acetate was approved under the brand name Geref in two forms. A diagnostic formulation, approved in December 1990, was used to evaluate the pituitary gland's ability to secrete growth hormone. A treatment formulation, approved in September 1997, was indicated for idiopathic growth hormone deficiency in children with growth failure.

The manufacturer notified FDA in 2008 that it had discontinued both products, and the approvals were withdrawn in 2009. In the 2013 notice, FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness.

Two things follow, and marketing tends to mention only the first. Sermorelin was not pulled because FDA found it dangerous. But there is also no FDA-approved sermorelin on the market now, and the approvals that did exist were for children with growth hormone deficiency and for diagnostic testing, never for adult energy, body composition or aging. For a clear list of peptide drugs that currently carry approval, see the peptide medicines that are FDA-approved.

What does the evidence in adults show?

Less than the marketing implies.

The study most often cited is a small 1997 trial by Khorram, Laughlin and Yen in the Journal of Clinical Endocrinology and Metabolism. Nineteen older men and women received nightly injections of a GHRH(1-29) analogue, closely related to sermorelin but not identical, for 16 weeks after a four-week placebo period. GH secretion and IGF-1 rose. The researchers reported increased skin thickness in both sexes, increased lean body mass and improved insulin sensitivity in men only, and improvements in well-being and libido in men but not women.

That is an interesting physiological study. It is not evidence that sermorelin makes older adults stronger, healthier or longer-lived:

• Nineteen people is far too few to detect uncommon harms or to generalize.
• Sixteen weeks says nothing about long-term effects.
• A placebo run-in followed by active treatment is weaker than randomizing people to parallel treatment and placebo groups.
• Changes in lean mass or hormone levels are not the same as changes in things people actually care about, like strength, falls, fractures or quality of life.

We are not aware of large, long-term randomized trials of sermorelin in healthy adults measuring those outcomes. That is the gap between "raises IGF-1" and "helps you," and it is the same gap that has repeatedly tripped up hormone-based anti-aging claims. Our article on why testosterone therapy is not anti-aging treatment makes the parallel argument for another hormone.

What are the risks and unknowns?

Because compounded sermorelin has no current FDA-approved labeling, there is no up-to-date, regulator-reviewed list of adverse effects for how it is used today. What we can say:

• Injection-related effects. Like other injected peptides, reactions at the injection site are a common complaint.
• Effects of raising GH and IGF-1. The labeling for tesamorelin, an FDA-approved GHRH analogue, is a useful guide to what clinicians watch for in this drug class. It warns that tesamorelin raises IGF-1 and that the long-term effects of prolonged elevation are unknown, that it may cause glucose intolerance or diabetes, and that fluid retention can show up as swelling, joint pain or carpal tunnel symptoms. It is contraindicated in active malignancy and in pregnancy. Sermorelin is a different molecule and those warnings are not its labeling, but the underlying biology is similar.
• Cancer history. IGF-1 is a growth factor. Anyone with a current or past cancer, or with a condition that raises cancer risk, needs a careful conversation before considering anything designed to raise it.
• Compounding quality. A compounded product is only as good as the pharmacy that makes it. Knowing which licensed pharmacy prepares it, and on what legal basis, matters.

Where does sermorelin stand legally now?

Sermorelin prescribed in the US today is generally a compounded preparation. Its regulatory footing for compounding has been discussed differently by different sources, and the rules governing bulk substances have been in flux for several peptides in 2026. We are not going to state a specific compounding status here, because that is the kind of detail that goes stale fast. A prescriber working with a licensed pharmacy should be able to tell you exactly what the pharmacy's legal basis is on the day you ask, and whether it is a 503A pharmacy or a 503B outsourcing facility.

For athletes the answer is simple. The WADA Prohibited List names sermorelin, alongside GHRH and its other analogues such as CJC-1295 and tesamorelin, under class S2. It is prohibited at all times. See peptides and drug testing for more.

Rules change. Verify anything time-sensitive with FDA or, for sport, with USADA or your governing body.

How does sermorelin compare with other GH-axis peptides?

Sermorelin belongs to a family. Tesamorelin is a modified GHRH analogue that is FDA-approved (as Egrifta SV) for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; we cover it, and why that narrow approval matters, in tesamorelin: the approved GHRH analogue and its limits. CJC-1295 is a longer-acting GHRH analogue, and ipamorelin works through a different receptor, the ghrelin receptor. Neither is FDA-approved. Those are explained in CJC-1295 and ipamorelin.

What a sensible evaluation looks like

Most people interested in sermorelin are not looking for a hormone. They are looking for something: more energy, better sleep, easier recovery, a body composition that matches the effort they are putting in. Those are reasonable goals, and they have many possible explanations.

A clinician worth seeing will want to understand the whole picture before discussing any peptide. That usually means a detailed history and medication review, screening for common and treatable contributors such as thyroid problems, low testosterone, sleep apnea, iron deficiency, poorly controlled blood sugar or mood changes, and baseline labs, which may include IGF-1. True adult growth hormone deficiency is diagnosed with specific testing, typically by an endocrinologist, and when it is present, approved growth hormone treatment is the established route.

Our peptide therapy consultations follow that order: your goals and history first, then an honest look at options, including what sermorelin can and cannot be expected to do. Sometimes the right next step is lab work or a sleep study rather than any prescription, and sometimes it is "this isn't right for you." If you would like to have that conversation, you can book a consultation with a licensed clinician.

Common questions

Is sermorelin the same as HGH?

No. Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone. It signals the pituitary to release your own growth hormone. HGH (somatropin) is the hormone itself.

Is sermorelin FDA-approved?

It was. Geref (sermorelin acetate) was approved for pediatric growth hormone deficiency and for diagnostic testing, then discontinued by its manufacturer in 2008. FDA later found it was not withdrawn for safety or effectiveness reasons. No FDA-approved sermorelin product is currently marketed, and compounded sermorelin is not FDA-approved.

Is sermorelin safer than growth hormone?

That has not been established. Because it works through the body's feedback loop, it may be less likely to push GH far beyond physiological levels, but there are no large head-to-head or long-term trials comparing the two in healthy adults.

Does sermorelin raise IGF-1?

In small studies, GHRH(1-29) and closely related analogues raised GH secretion and IGF-1 in older adults. How much it does so varies with age and pituitary function, which is one reason clinicians check labs before and during treatment.

Can athletes use sermorelin?

Not if they are subject to anti-doping rules. Sermorelin is listed under S2 of the WADA Prohibited List and is prohibited at all times.